231 related articles for article (PubMed ID: 33765714)
21. Implication of KDR Polymorphism rs2071559 on Therapeutic Outcomes and Safety of Postoperative Patients with Gastric Cancer Who Received S-1-Based Adjuvant Chemotherapy: A Real-World Exploratory Study.
Meng L; Cao J; Kang L; Xu G; Yuan DW; Li K; Zhu K
Pharmgenomics Pers Med; 2023; 16():1027-1039. PubMed ID: 38046381
[TBL] [Abstract][Full Text] [Related]
22. Influence of Two DNA Repair Pathway Polymorphisms in Colorectal Cancer Risk in Southwest Iran.
Hosseini SM; Mohammadiasl J; Talaiezadeh A; Alidadi R; Bijanzadeh M
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1919-1924. PubMed ID: 32711416
[TBL] [Abstract][Full Text] [Related]
23. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
Lv H; Li Q; Qiu W; Xiang J; Wei H; Liang H; Sui A; Liang J
Cancer Invest; 2013 Jan; 31(1):24-8. PubMed ID: 23327191
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of genetic variants XRCC1 rs1799782, APEX1 rs1760944, and MUTYH rs3219489 for adjuvant concurrent chemoradiotherapy outcomes in oral squamous cell carcinoma patients.
Senghore T; Chien HT; Wang WC; Chen YX; Young CK; Huang SF; Yeh CC
Pharmacogenomics J; 2020 Dec; 20(6):813-822. PubMed ID: 32461665
[TBL] [Abstract][Full Text] [Related]
26. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
[TBL] [Abstract][Full Text] [Related]
27. Lack of Association between an XRCC1 Gene Polymorphism and Colorectal Cancer Survival in Thailand.
Siewchaisakul P; Suwanrungruang K; Poomphakwaen K; Wiangnon S; Promthet S
Asian Pac J Cancer Prev; 2016; 17(4):2055-60. PubMed ID: 27221895
[TBL] [Abstract][Full Text] [Related]
28. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.
Chen J; Zhao QW; Shi GM; Wang LR
J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080
[TBL] [Abstract][Full Text] [Related]
29. Association between X-ray repair cross-complementing group 1(XRCC1) Arg399Gln polymorphism and endometriosis: A systematic review and meta-analysis.
Lv MQ; Wang J; Yu XQ; Hong HH; Ren WJ; Ge P; Zhou DX
Eur J Obstet Gynecol Reprod Biol; 2017 Nov; 218():12-20. PubMed ID: 28926725
[TBL] [Abstract][Full Text] [Related]
30. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
[TBL] [Abstract][Full Text] [Related]
31. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
[TBL] [Abstract][Full Text] [Related]
32. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
[TBL] [Abstract][Full Text] [Related]
33.
Meza-Espinoza JP; Peralta-Leal V; Durán-González J; Macías-Gómez N; Bocanegra-Alonso A; Leal-Ugarte E
Genet Res (Camb); 2023; 2023():5565646. PubMed ID: 37829155
[TBL] [Abstract][Full Text] [Related]
34. The XRCC1 Arg399Gln gene polymorphism and risk of colorectal cancer: a study in Kashmir.
Khan NP; Pandith AA; Yousuf A; Khan NS; Khan MS; Bhat IA; Nazir ZW; Wani KA; Hussain MU; Mudassar S
Asian Pac J Cancer Prev; 2013; 14(11):6779-82. PubMed ID: 24377605
[TBL] [Abstract][Full Text] [Related]
35. XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.
Tengström M; Mannermaa A; Kosma VM; Hirvonen A; Kataja V
Anticancer Res; 2014 Jun; 34(6):3031-7. PubMed ID: 24922669
[TBL] [Abstract][Full Text] [Related]
36. Lack of correlation between X-ray repair cross-complementing group 1 gene polymorphisms and the susceptibility to colorectal cancer in a Malaysian cohort.
Lau TP; Lian LH; Cheah PL; Looi LM; Roslani AC; Goh KL; Lee PC; Chua KH
Eur J Cancer Prev; 2017 Nov; 26(6):506-510. PubMed ID: 28059856
[TBL] [Abstract][Full Text] [Related]
37. [The impact of genetic variation of KDR on clinical outcomes of advanced colorectal cancer patients treated by first line bevacizumab based regimens].
Wang HX; Mei X; Gong TX; Han N; Liu P; Wang J; Zhang ZM
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2737-2742. PubMed ID: 30220171
[No Abstract] [Full Text] [Related]
38. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
Cui Z; Yin Z; Li X; Wu W; Guan P; Zhou B
BMC Cancer; 2012 Feb; 12():71. PubMed ID: 22339849
[TBL] [Abstract][Full Text] [Related]
39. The Possible Role of XRCC1 Gene Polymorphisms with Idiopathic Non-obstructive Azoospermia in Southeast Turkey.
Akbas H; Balkan M; Binici M; Gedik A
Urol J; 2019 Aug; 16(4):380-385. PubMed ID: 31004343
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
